Droperidol
5mg/2ml ampoules (IV, IM)
Executive Summary
(Updated January 2023)
Executive Summary
Droperidol is a first generation antipsychotic (so-called typical antipsychotics, same class as haloperidol) that acts as a D2 dopamine receptor antagonist. Droperidol also has some histamine and serotonin antagonist properties (3).
It has a significant potential role in the ED because of its efficacy to treat a variety of clinical conditions, including undifferentiated agitation, migraine, vertigo, nausea, vomiting, cannabinoid hyperemesis, and pain (3, 4, 5, 6, 7, 10, 12).
Droperidol or olanzapine are considered first-line medications to treat acute severe agitation in psychiatric patients, and both can be used in combination with benzodiazepines (7, 12).
Its use differs amongst geographical locations, clinicians and ED protocols. Some EDs do indicate it on a daily basis, others don't; this phenomena is explained to a great degree because of the US-FDA Black Box Warning issued in 2001 (2). This warning has been deeply questioned (1, 3, 6, 11, 13), this is why droperidol has been regaining popularity and its use has been increasing over the last decade (11). Nonetheless it should not be used on patients with long QT syndrome or at an increased risk of QT prolongation.
Adult dose for undifferentiated agitation in the ED (6, 12)
5-10mg IM
Time to adequate sedation is usually 10 to 20 min with a time to peak effect of 30 min
Adult dose for migraine, acute vertigo, nausea or vomiting and cannabinoid hyperemesis (2, 4, 5, 10)
1.25-2.5mg IV or IM
Adult dose
Adult dose for undifferentiated agitation in the ED (6, 12)
5-10mg IM
Time to adequate sedation is usually 10 to 20 min with a time to peak effect of 30 min.
If used IM, may repeat dose in 30 min (max 20 mg in 24 hours).
If used IV, may repeat dose in 5 min (max 20 mg in 24 hours)
May be administered as monotherapy or in combination with a benzodiazepine.
Adult dose for migraine, acute vertigo, nausea or vomiting and cannabinoid hyperemesis (2, 4, 5, 10)
1.25-2.5mg IV or IM
For nausea and vomiting an initial dose of 0.625mg may be sufficient
Additional dose of 1.25mg may be necessary
Indications
Indications
US FDA-labeled (2):
Nausea and vomiting treatment and prevention (post-operative, post-procedural)
Off-label:
Agitation
Acute vertigo
Cannabinoid hyperemesis syndrome
Headache (migraine)
Chronic and neuropathic pain
⚠ Warnings and Precautions
US-FDA Black Box Warning issued in 2001, label citation (2)
“Cases of QT prolongation and/or torsade de pointes have been reported in patients receiving droperidol at doses at or below recommended doses. Some cases have occurred in patients with no known risk factors for QT prolongation and some cases have been fatal. Due to its potential for serious proarrhythmic effects and death, droperidol should be reserved for use in the treatment of patients who fail to show an acceptable response to other adequate treatments, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS).
Cases of QT prolongation and serious arrhythmias (e.g., torsade de pointes) have been reported in patients treated with droperidol. Based on these reports, all patients should undergo a 12-lead ECG prior to administration of droperidol to determine if a prolonged QT interval (i.e., QTc greater than 440 msec for males or 450 msec for females) is present. If there is a prolonged QT interval, droperidol should NOT be administered. For patients in whom the potential benefit of droperidol treatment is felt to outweigh the risks of potentially serious arrhythmias, ECG monitoring should be performed prior to treatment and continued for 2-3 hours after completing treatment to monitor for arrhythmias.
Droperidol is contraindicated in patients with known or suspected QT prolongation, including patients with congenital long QT syndrome.
Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval).
Other risk factors may include age over 65 years, alcohol abuse, and use of agents such as benzodiazepines, volatile anesthetics, and IV opiates. Droperidol should be initiated at a low dose and adjusted upward, with caution, as needed to achieve the desired effect.”
Questioning of the US-FDA Black Box Warning
A copious amount of clinical data, review articles and society statements have emerged over the last decade defending droperidol safety when used properly and in the doses that usually are sufficiently needed in the ED (1, 3).
Society positions, review articles, expert opinion:
2021 ACEP - American College of Emergency Physicians
2021 Severe Agitation in the ED Task Force Report
ACEP Task Force Report on Hyperactive Delirium with Severe Agitation in Emergency Settings, 20212021 Policy Statement
ACEP - Use of Droperidol in the Emergency Department 2021
2020 EM-RAP - Emergency Medicine Reviews and Perspectives
Droperidol is Back by Reuben Strayer
2019 FOAMcast - An Emergency Medicine Podcast
FOAMCAST 2019 Droperidol (and Haloperidol) Review by emergency physicians Jeremy Faust and Lauren Westafer
2015 American Academy of Emergency Medicine (AAEM)
Pregnancy and lactation
Pregnancy
AU-TGA pregnancy category: C
US-FDA pregnancy category: C
Lactation
There are no published data about droperidol on its excretion on breast milk, but available molecular data on its pharmacokinetic characteristics (high plasma protein binding, large volume of distribution and short half-life), make it very unlikely its excretion into breast milk in significant amounts (14).
Therefore it should be considered safe during breastfeeding at least in small and short term doses usually given in the ED.
References
Overview, label and safety
Perkins J, Ho JD, Vilke GM, DeMers G. American Academy of Emergency Medicine Position Statement: Safety of Droperidol Use in the Emergency Department. J Emerg Med. 2015;49(1):91-97. doi:10.1016/j.jemermed.2014.12.024
Pubmed
NIH-NLM (National Institutes of Health - National Library of Medicine). DailyMed. Label: DROPERIDOL injection, solution. Updated in October 2019.
DailyMedGaw CM, Cabrera D, Bellolio F, Mattson AE, Lohse CM, Jeffery MM. Effectiveness and safety of droperidol in a United States emergency department. Am J Emerg Med. 2020;38(7):1310-1314. doi:10.1016/j.ajem.2019.09.007
Science Direct (Open Access)
Specific indications
Irving C, Richman PB, Kaiafas C, Eskin B, Ritter A, Allegra J. Droperidol for the treatment of acute peripheral vertigo. Am J Emerg Med. 1999;17(1):109-110. doi:10.1016/s0735-6757(99)90037-2
PubmedMiner JR, Fish SJ, Smith SW, Biros MH. Droperidol vs. prochlorperazine for benign headaches in the emergency department. Acad Emerg Med. 2001;8(9):873-879. doi:10.1111/j.1553-2712.2001.tb01147.x
PubmedDORM Study - Isbister GK, Calver LA, Page CB, Stokes B, Bryant JL, Downes MA. Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Ann Emerg Med. 2010;56(4):392-401.e1. doi:10.1016/j.annemergmed.2010.05.037
PubmedChan EW, Taylor DM, Knott JC, Phillips GA, Castle DJ, Kong DC. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Ann Emerg Med. 2013;61(1):72-81. doi:10.1016/j.annemergmed.2012.07.118
PubmedDORM II Study - Calver L, Page CB, Downes MA, et al. The Safety and Effectiveness of Droperidol for Sedation of Acute Behavioral Disturbance in the Emergency Department. Ann Emerg Med. 2015;66(3):230-238.e1. doi:10.1016/j.annemergmed.2015.03.016
PubmedFuryk JS, Meek RA, Egerton-Warburton D. Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. Cochrane Database Syst Rev. 2015;2015(9):CD010106. Published 2015 Sep 28. doi:10.1002/14651858.CD010106.pub2
Pubmed Central (Open Access)Lee C, Greene SL, Wong A. The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome. Clin Toxicol (Phila). 2019;57(9):773-777. doi:10.1080/15563650.2018.1564324
PubmedKramer KJ. The Surprising Re-emergence of Droperidol. Anesth Prog. 2020;67(3):125-126. doi:10.2344/anpr-67-03-14
Pubmed Central (Open Access)ACEP Task Force Report on Hyperactive Delirium with Severe Agitation in Emergency Settings. Approved by the ACEP Board of Directors, June 23, 2021.
ACEPACEP Policy Statement. Use of Droperidol in the Emergency Department, 2021.
ACEP (Open Access)APILAM (Association for promotion of and cultural and scientific research into breastfeeding). e-lactancia. Droperidol. Updated June 2022. Accessed February 12, 2023.
E-lactancia
® 2023 EMDrugs. All rights reserved.
contact@emdrugs.com
DISCLAIMER
⚠ This website provides general information and discussion about medications, health, and related subjects. The words and other content provided in this website, and in any linked materials, are not intended and should not be construed as medical advice. If the reader or any other person has a medical concern, he or she should consult with an appropriately-licensed physician or other legally accredited health care worker in the country that resides or is visiting.
Please do not delay your medical concerns and potential health emergencies by searching information in this website, instead look out for medical opinion in the services that exist with that specific purpose and work under the respective local health-care regulations.
The views expressed on this blog and website have no relation to those of any academic, hospital, practice or other institution with which the authors are affiliated.
For other instances, the authors of this website do not have any conflict of interest with any institution or pharmaceutical company in particular, and do not receive any compensation about any licenced drug mentioned in the website. In the same matter, the website is not intended to recommend any specific patented medication.
EMDrugs Team